OSRH

OSRH is a former blank-check shell that only became an operating company on Feb 14, 2025, and by its own admission 'has not generated revenue from product sales' — the $2.91M of FY2025 revenue (down 17.7% YoY) sits on a 20.4% gross margin and is dwarfed by a -$27.1M net loss (net margin -931%). This is a portfolio of pre-commercial subsidiaries (VXM01 oral cancer immunotherapy, design-augmented biologics, and the Jan-2026 Woori IO glucose-biosensing acquisition), and its value depends entirely on clinical success, regulatory approval, and — repeatedly flagged in the MD&A — 'access to additional financing.' None of that is de-risked here.

The balance sheet is the disqualifier. Cash is just $1.70M against a -$4.33M operating burn, meaning less than a half-year of runway before it must raise again. Current liabilities exploded 395.6% to $17.2M versus only $2.82M of current assets — a ~$14.4M working-capital deficit and a current ratio near 0.16. Share count already grew 71.8% to 33.1M, and the Joinder put-option exchange (5.3M more OSRH shares issued Jan 2026) plus inevitable financing point to relentless dilution. The market underscores the skepticism: reported equity is $127M but the company is priced at a $10.6M market cap, i.e. ~8 cents on the book-value dollar — investors simply do not trust the carried assets (largely intangibles/goodwill from the combination).